文献速递炎症性肠病

超声、生物电阻抗分析与人体测量作为炎症性肠病患者骨骼肌质量即时检测的准确性

Accuracy of ultrasound, bioelectrical impedance analysis and anthropometry as point-of-care measurements of skeletal muscle mass in patients with inflammatory bowel disease.
PubMed 文献 · Aliment Pharmacol Ther · 2023-06-12

本研究纳入54例炎症性肠病(IBD)患者和30名健康对照,前瞻性比较手臂与双腿超声、生物电阻抗分析(BIA)、人体测量与参考标准全身双能X线吸收法(DXA)测量肌肉量的准确性。IBD患者中手臂和腿部超声与DXA来源骨骼肌指数(SMI)一致性最佳(平均差0 kg/m²,95%一致性界限-1.3至1.3),BIA高估DXA来源SMI 1.07(-0.16至+2.30)kg/m²。17例接受生物制剂治疗者中,除中臂围外各方法均能反映治疗引起的肌肉量变化;作者认为超声是IBD患者测量肌肉量的首选无创检测。

要点

  • IBD患者中手臂和腿部超声与DXA来源SMI一致性最佳,平均差0 kg/m²(95%一致性界限-1.3至1.3)。
  • BIA高估DXA来源SMI 1.07 kg/m²(95%一致性界限-0.16至+2.30)。
  • 除中臂围外,各肌肉评估方法均能反映生物制剂治疗引起的肌肉量变化。

核心结论

  • 手臂和腿部超声在测量肌肉量准确性上优于其他即时检测方法。
  • 除中臂围外,所有方法均能反映治疗引起的肌肉量变化。
  • 超声是IBD患者测量肌肉量的首选无创检测。

研究设计与样本

  • 前瞻性研究,纳入54例成人IBD患者和30名健康对照。
  • 采用优势臂及双腿超声、BIA、人体测量和DXA评估肌肉量。
  • 活动期IBD患者在启动生物制剂诱导治疗后≥13周再次评估,共17例接受生物制剂治疗。

主要发现

  • IBD患者中所有肌肉评估均与DXA来源SMI显著相关。
  • IBD患者中手臂和腿部超声与DXA来源SMI平均差0 kg/m²(95%一致性界限-1.3至1.3)。
  • BIA高估DXA来源SMI 1.07 kg/m²(95%一致性界限-0.16至+2.30)。
  • 17例接受生物制剂治疗者中,DXA来源SMI百分比变化与所有其他肌肉评估技术的百分比变化显著相关。
  • 应答者(n=9)从基线至随访DXA来源SMI由平均7.8升至8.5 kg/m²(p=0.004),手臂和腿部超声由300升至343 cm²(p=0.021),BIA由9.2升至9.6 kg/m²(p=0.011)。

临床怎么用

  • 作者认为超声是IBD患者测量肌肉量的首选无创检测。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Disturbance of skeletal muscle mass has clinically important implications in patients with inflammatory bowel disease (IBD), but accurate quantification requires radiation-intense techniques. AIMS: We aimed to compare point-of-care muscle assessments and their change with therapy with those using reference-standard whole-body dual energy X-ray absorptiometry (DXA). METHODS: Adult patients with IBD and healthy controls underwent prospective assessment of muscularity by ultrasound of the dominant arm and both thighs, bioelectrical impedance analysis (BIA), anthropometric measurements, and DXA. Patients with active IBD were assessed again ≥13 weeks after initiating biologic induction therapy. RESULTS: In 54 patients with IBD and 30 controls, all muscle assessments correlated significantly with DXA-derived skeletal muscle index (SMI). In IBD, ultrasound of the arm and legs had the best agreement with DXA-derived SMI (mean difference 0 kg/m2 , 95% limits of agreement -1.3 to 1.3), while BIA overestimated DXA-derived SMI by 1.07 (-0.16 to +2.30) kg/m2 . In 17 patients who underwent biologic therapy, the percentage change in DXA-derived SMI correlated significantly with the percentage change in all other muscle assessment techniques. Responders (n = 9) increased SMI from baseline to follow-up when derived from DXA (mean 7.8-8.5 kg/m2 , p = 0.004), ultrasound of the arm and legs (300-343 cm2 , p = 0.021) and BIA (9.2-9.6 kg/m2 , p = 0.011). CONCLUSIONS: Ultrasound of the arm and legs out-performed other point-of-care methods in its accuracy of measuring muscle mass. All methods, except mid-arm circumference, were responsive to therapy-induced change. Ultrasound is the preferred non-invasive test for measuring muscle mass in patients with IBD.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Nguyen AL, Burns M, Herath M, et al. Accuracy of ultrasound, bioelectrical impedance analysis and anthropometry as point-of-care measurements of skeletal muscle mass in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2023. PMID: 37305984. doi:10.1111/apt.17607

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。